Generics in France

Date: January 4, 2016
Pages: 32
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GD1EF4ABE3BEN
Leaflet:

Download PDF Leaflet

Generics in France
INTRODUCTION

Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the France generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

HIGHLIGHTS
  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The French generics market is expected to generate total revenues of $4.2bn in 2015, representing a compound annual growth rate (CAGR) of 2% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 32.8 % of total pharma volume in 2015.
  • Generic sales were hit by price cuts in 2014. However, an advertising campaign will begin at the end of 2015, which aims to build confidence in generic drugs. This should see the market begin to grow again within the next few years.
FEATURES
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in France
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the France economy
KEY QUESTIONS ANSWERED
  • What was the size of the France generics market by value in 2015?
  • What will be the size of the France generics market in 2020?
  • What factors are affecting the strength of competition in the France generics market?
  • How has the market performed over the last five years?
  • How large is France’s generics market in relation to its regional counterparts?
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Les Laboratoires Servier
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country Data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: France generics market value: $ billion, 2011–15(e)
Table 2: France generics market volume: % of total pharma volume, 2011–15(e)
Table 3: France generics market geography segmentation: $ billion, 2015(e)
Table 4: France generics market value forecast: $ billion, 2015–20
Table 5: France generics market volume forecast: % of total pharma volume, 2015–20
Table 6: Les Laboratoires Servier: key facts
Table 7: Sandoz International GmbH: key facts
Table 8: Sanofi SA: key facts
Table 9: Sanofi SA: key financials ($)
Table 10: Sanofi SA: key financials (€)
Table 11: Sanofi SA: key financial ratios
Table 12: Teva Pharmaceutical Industries Limited: key facts
Table 13: Teva Pharmaceutical Industries Limited: key financials ($)
Table 14: Teva Pharmaceutical Industries Limited: key financial ratios
Table 15: France size of population (million), 2011–15
Table 16: France gdp (constant 2005 prices, $ billion), 2011–15
Table 17: France gdp (current prices, $ billion), 2011–15
Table 18: France inflation, 2011–15
Table 19: France consumer price index (absolute), 2011–15
Table 20: France exchange rate, 2011–15

LIST OF FIGURES

Figure 1: France generics market value: $ billion, 2011–15(e)
Figure 2: France generics market volume: % of total pharma volume, 2011–15(e)
Figure 3: France generics market geography segmentation: % share, by value, 2015(e)
Figure 4: France generics market value forecast: $ billion, 2015–20
Figure 5: France generics market volume forecast: % of total pharma volume, 2015–20
Figure 6: Forces driving competition in the generics market in France, 2015
Figure 7: Drivers of buyer power in the generics market in France, 2015
Figure 8: Drivers of supplier power in the generics market in France, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2015
Figure 11: Drivers of degree of rivalry in the generics market in France, 2015
Figure 12: Sanofi SA: revenues & profitability
Figure 13: Sanofi SA: assets & liabilities
Figure 14: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 15: Teva Pharmaceutical Industries Limited: assets & liabilities
Skip to top


Egis Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 10 pages
Sanofi-Aventis Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 10 pages

Ask Your Question

Generics in France
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: